Advancing neuropsychiatric drug discovery
Preclinical models for Major Depressive Disorder (MDD) & Post-Traumatic Stress Disorder (PTSD)
Building better models for neuropsychiatric drug discovery
Developing effective therapies for MDD and PTSD remains challenging due to the complexity of modelling human behaviour, treatment resistance and the preclinical-to-clinical translational gap.
This webinar will explore validated preclinical models for MDD and PTSD, model selection strategies, relevant behavioural paradigms, and integrated behavioural and biomarker assessments.
Learn how translational endpoints can enhance clinical relevance, strengthen candidate selection and help de-risk neuropsychiatric drug discovery programmes.
The challenges behind translation
Neuropsychiatric drug discovery requires models that can capture complex disease biology and provide meaningful translational insights.
Modelling human behaviour
Capturing complex behavioural phenotypes in preclinical models remains a significant scientific challenge.
Treatment resistance
Understanding treatment response and resistance is essential for improving candidate selection.
Translational gap
Connecting preclinical findings with clinically meaningful outcomes remains a critical hurdle.
Clinical endpoints
Selecting relevant behavioural and biomarker endpoints can strengthen clinical relevance.
From model selection to translational confidence
A carefully designed preclinical strategy can improve the relevance of study outcomes and support better decision-making throughout drug discovery.
- ✓ Selection of relevant and validated preclinical models
- ✓ Capturing appropriate behavioural paradigms
- ✓ Integrated behavioural and biomarker assessments
- ✓ Identification of relevant translational endpoints
- ✓ Practical discussion through 1–2 case studies
What will be explored
The session will examine how preclinical model selection, behavioural assessments and biomarkers can be integrated to generate more clinically relevant insights.
Practical case study discussions will highlight how these approaches can support candidate selection and reduce translational risk.
What attendees will take away
Validated models
Explore validated preclinical models for Major Depressive Disorder and PTSD and their application in drug discovery.
Translational endpoints
Understand how behavioural and translational endpoints can improve clinical relevance.
Better candidate selection
Learn how integrated assessments can strengthen candidate selection and help de-risk discovery programmes.
Meet the speaker.
With 22+ years of experience in drug discovery and CRO services, Sachin specializes in preclinical pharmacology and translational research. His scientific contributions include international publications, 15+ conference abstracts, and programs that have advanced three discovery-stage molecules into clinical trials.
Reserve your place for the session
Join us to explore practical approaches to preclinical modelling and translational assessment in neuropsychiatric drug discovery.
Series 2 Upcoming..
Advancing neurodegenerative drug discovery
Preclinical models for Parkinson’s Disease, Alzheimer’s Disease & ALS.